Quick Answer
Denali Therapeutics Inc. reported Research And Development Expense of $418.78 million for the year ending 2025.
- Denali Therapeutics Inc. showed an increase of +5.6% in Research And Development Expense from 2024 to 2025.
- This data is from Denali Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $18.47 million | Q2 2017: $19.00 million | Q3 2017: $18.52 million | Q1 2018: $20.82 million | Q2 2018: $52.13 million | Q3 2018: $30.32 million | Q1 2019: $37.40 million | Q2 2019: $51.88 million | Q3 2019: $52.54 million | Q1 2020: $51.02 million | Q2 2020: $53.15 million | Q3 2020: $53.70 million | Q1 2021: $60.21 million | Q2 2021: $65.71 million | Q3 2021: $71.56 million | Q1 2022: $86.10 million | Q2 2022: $92.74 million | Q3 2022: $87.79 million | Q1 2023: $128.82 million | Q2 2023: $97.52 million | Q3 2023: $89.74 million | Q1 2024: $107.02 million | Q2 2024: $91.40 million | Q3 2024: $98.24 million | Q1 2025: $116.23 million | Q2 2025: $102.70 million | Q3 2025: $101.95 million.
- Over the full 10 years of available data (2016 to 2025), Denali Therapeutics Inc.'s Research And Development Expense has grown by 453.2%.
- Historical annual values: Fiscal year 2025: $418.78 million | Fiscal year 2024: $396.44 million | Fiscal year 2023: $423.88 million | Fiscal year 2022: $358.73 million | Fiscal year 2021: $265.35 million | Fiscal year 2020: $212.62 million | Fiscal year 2019: $193.38 million | Fiscal year 2018: $143.18 million | Fiscal year 2017: $74.46 million | Fiscal year 2016: $75.70 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: